weight loss

retatrutide

Retatrutide: The Triple Agonist That Makes GLP-1s Look Basic

Eli Lilly's retatrutide achieved 28.7% weight loss and 76% knee pain reduction in Phase 3. Seven more readouts coming in 2026.

Petrelintide infographic showing 8.6% weight loss with zero nausea vs placebo — amylin analogue Phase 1 RCT results

obesity pharmacotherapy

Petrelintide: The Weight Loss Drug That Works Without the Nausea

A new amylin analogue (petrelintide) posted Phase 1 results: 8.6% body weight reduction at 16 weeks, nausea rate identical to placebo. Here's what that means for GLP-1 dropouts.